6887 — Sunshine Lake Pharma Share News
0.000.00%
Last trade - 00:00- HK$22.09bn
- HK$26.58bn
- CNY4.82bn
Brief: Sunshine Lake Pharma Expects HY Loss Attributable RMB590 Million
Brief: Sunshine Lake Pharma Says Zhang Yushuai Purchases 1.5 Million H Shares
Brief: Sunshine Lake Pharma Obtains Nmpa Approval For Insulin Degludec Injection
Brief: Sunshine Lake Pharma Says Controlling Shareholder To Increase Shareholding By Hk$300 Million-Hk$600 Million In Next Six Months
Brief: Sunshine Lake Pharma's Insulin Glargine Injection Obtained Marketing Approval From U.S. FDA
Brief: Sunshine Lake Pharma Enters Partnership To Establish Limited Partnership Fund
Brief: Sunshine Lake Pharma Elects Zhang Yingjun As Chairman Of Second Session Of Board
Brief: Sunshine Lake Pharma Says NMPA Accepts Clinical Trial Application For HEC-921 Injection
Brief: Lannett Company FDA Approval Of Langlara As Biosimilar To Lantus
Sunshine Lake Pharma jumps most on record on FDA marketing nod for insulin injection
Brief: Sunshine Lake Pharma Says US FDA Approves Co's Insulin Glargine Injection
Brief: Sunshine Lake Pharma Says Mixed Protamine Human Insulin Injection (30R) Obtains NMPA Marketing Approval
Brief: Sunshine Lake Pharma Says NMPA Accepts Marketing Authorisation Application For Vonoprazan Fumarate And Sodium Chloride Injection
Brief: Sunshine Lake Pharma Posts FY Revenue Of RMB4,815.07 Million
Brief: Sunshine Lake Pharma Expects Net Profit Attributable Of RMB0.27 Billion For Year
Brief: Sunshine Lake Pharma Says China's NMPA Accepts Investigational New Drug Application For HEC-648 Injection
Brief: Sunshine Lake Pharma Enters Strategic Agreement With Shenzhen Xtalpi Technology
Brief: Sunshine Lake Pharma Says Olorigliflozin Capsules Gets Marketing Aproval From China NMPA
China's Sunshine Lake Pharma climbs on mulling to buy back shares